The induction of a tolerance break against the tumor via PD-1/PD-L1 blockade can lead to immune dysregulation, namely immune-related adverse events (irAEs), which clinically manifest as symptoms including dermatologic, gastrointestinal, hepatic, endocrine, and pulmonary events.[16] In addition to these unique AEs, treatment-related adverse events (trAEs) include fatigue, anorexia, nausea, and diarrhoea.[5,14,17–21]. This evidence concerns the gene PDCD1 and neoplasm.